Kornimate/medical-research-clean huggingface dataset:
late incomplete stent apposition evaluation ii: comparison between polimer-based and no-polimer stent system. ivus based study

Conditions: Coronary Artery Disease

Summary: vascular effects evaluation after non-polimeric and polimeric paclitaxel stent implantation.in particular the investigators will use taxus )as a polimeric stent)and axxion (as a non-polimeirc)stent system. the investigators will look at late stent malapposition by means of intracoronary ultrasound imaging technique (ivus) at baseline and 9 months follow-up. the investigators sought to compare the two stent types with the same drug to verify the polimer role. the polimer itself seems to provoke inflammation and hypersensibility if the arterial wall and it seems to be the base of a process of positive remodeling found at drug eluting stent implantation site. this positive remodeling is the mechanism producing late stent malapposition which on its turn can determine stent thrombosis, as demonstrated by pathological studies. at the same time the investigators will study the incidence of clinical events like myocardial infarction, stent thrombosis, tlr and death along with the incidence of angiographic restenosis at 2 years follow up.


Eligibility criteria:
inclusion criteria: * patients with coronary artery stenosis in one, two or three vessels, and with objective evidence of isquemia. * the stenosis must allow ivus analisis, must be treatable with angioplasty with stent * target vessel diameter must be between 2.25- 4 mm with qca. * patients must sign informed consent * patients and their physician must accept the angiographic follow-up exclusion criteria: * 18 years old patients * sca within the last 72 hours, or patients with ck twice over the upper normal limit * pregnancy * target vessel diameter \ 4 mm by qca * previous brakitherapy or des in the target lesion * restenotic lesion * -allergy to aspirin, clopidogrel or ticlopidin * patients enrolled in other studies or trials * by-pass graft lesions * real bifurcationa lesions * severe renal insufficiency (creatinin clearance \< 30 ml/min). * severe liver failure(got y gpt \> 3 times the upper normal limit) * life expectancy \< 1 year because of other pathologies

Keywords: late stent malapposition stent thrombosis ivus non-polimeric stent
walking training with partial body weight support on static and dynamic surfaces in stroke survivers

Conditions: Stroke

Summary: the purpose of this study is evaluate the effects of walking training with partial body weight support on static (floor) and dynamic (treadmill) surfaces in individuals with hemiparesis due to stroke. for this purpose, two training protocols will be employed in three experimental groups: g1 will do the walking training with partial body weight support on static surfaces and g2 will do the walking training with partial body weight support on dynamic surfaces


Eligibility criteria:
inclusion criteria: * one-sided hemiparesis, no heart disease (or medical clearance to participate in the study), no orthopedic impairments and / or neurological symptoms that may alter the the gait, no history of thrombophlebitis or deep vein thrombosis, ability to understand and follow verbal commands, can walk alone or with canes of approximately 10 m; spasticity degree mild to moderate in the affected lower limb with levels of classification between 0 and 2 in the ashworth spasticity scale modified exclusion criteria: * heart frequency increase more than 75% of the maximum or have any other general instability during training that may lead risk for the health during the training,

Keywords: rehabilitation gait stroke biomechanics
safety and effectiveness of the koko device to treat primary abnormal postpartum uterine bleeding or hemorrhage

Conditions: Postpartum Hemorrhage; Immediate Postpartum Hemorrhage; Hemorrhage, Postpartum

Summary: the purpose of this study is to evaluate the safety and effectiveness of the koko™ device in the control and reduction of primary abnormal postpartum uterine bleeding or hemorrhage.

this ide study is designed to evaluate the effectiveness and safety of the koko™ device to treat primary abnormal postpartum uterine bleeding or hemorrhage. the study is literature controlled.

Eligibility criteria:
inclusion criteria: * adult female, 18 years of age or older at time of consent. * subject is able to understand and provide informed consent to participate in the study. * diagnosis of abnormal postpartum uterine bleeding (500 - 999 ml for vaginal birth) or postpartum hemorrhage (1000 - 1500 ml for vaginal or cesarean birth) with suspected atony within 24 hours after vaginal or cesarean birth. * ebl, to be determined when investigator is ready to have the koko packaging opened: vaginal birth: 500 - 1500 ml ebl or cesarean birth: 1000 - 1500 ml ebl. * failed first - line intervention of uterotonics and uterine massage/bimanual uterine massage to stop bleeding. note: uterotonic administration may continue concomitant with and post koko use. exclusion criteria: * ebl \>1500ml, to be determined when investigator is ready to have the koko packaging opened. * delivery at a gestational age \< 34 weeks or, if multiples, uterus is judged \<34 weeks size. * for cesarean births: cervix \< 2.5 cm dilated before use of koko. * abnormal postpartum uterine bleeding or hemorrhage that the investigator determines to require more aggressive treatment, including any of the following: 1. hysterectomy; 2. b-lynch suture; 3. uterine artery embolization or ligation; 4. hypogastric ligation. * known uterine anomaly. * ongoing intrauterine pregnancy. * placental abnormality including any of the following: 1. known placenta accreta; 2. retained placenta with known risk factors for placenta accreta (e.g., history of prior uterine surgery, including prior cesarean and placenta previa); 3. retained placenta without easy manual removal. * known uterine rupture. * unresolved uterine inversion. * subject has undergone intrauterine balloon therapy, uterine packing or use of other negative pressure system(s) for tamponade treatment of this episode of abnormal postpartum uterine bleeding or hemorrhage prior to use of the koko™ device. * current cervical cancer. * current purulent infection of vagina, cervix, uterus. * diagnosis of coagulopathy.
acute comfort of lubricant eye drops fid 112903

Conditions: Dry Eye

Summary: to evaluate the acute comfort and blurring profile between two artificial tears in dry eye patients.


Eligibility criteria:
inclusion criteria: * documented diagnosis of dry eye * must not have worn contact lenses for 1 week preceding enrollment exclusion criteria: * age related

Keywords: dry eye artificial tear
intravenous magnesium in wheezy bronchitis

Conditions: Wheezy Bronchitis

Summary: in infants and toddlers wheezy bronchitis is a common viral disease. to relieve wheezing symptoms bronchodilators or corticosteroids are commonly used but the efficacy is not always satisfactory. the purpose of this trial is to investigate the effectiveness of iv-magnesium in the treatment of moderate or severe bronchial obstruction associated with viral infection in small children. the study population will include the children attending the pediatric emergency department of oulu university hospital because of respiratory infection and bronchial obstruction that is not relieved with conventional treatment. after written consent from the parents, the children will be randomized to get either intravenous magnesium sulfate or isotonic nacl. the primary outcome is rdai (respiratory distress assessment instrument) scoring six hours from the infusion. secondary endpoints are rdai scoring and oxygen saturation at other time points and length of hospital stay. the sample size is 64 children at the age of 6 months to 4 years. if iv-magnesium is effective in relieving viral infection associated bronchial obstruction, that would be an important addition to the treatment of this common disease.

in infants and toddlers wheezy bronchitis is a common viral disease. to relieve wheezing symptoms bronchodilators or corticosteroids are commonly used but the efficacy is not always satisfactory. intravenous infusion of magnesium sulfate has been proven to be efficacious and safe for the treatment of acute asthma attacks in adults and school-aged children. the purpose of this trial is to investigate the effectiveness of iv-magnesium in the treatment of moderate or severe bronchial obstruction associated with viral infection in small children. the study population will include the children attending the pediatric emergency department of oulu university hospital because of respiratory infection and bronchial obstruction that is not relieved with conventional treatment. after written consent from the parents, the children will be randomized to get either intravenous magnesium sulfate or isotonic nacl. the primary outcome is rdai (respiratory distress assessment instrument) scoring six hours from the infusion. secondary endpoints are rdai scoring and oxygen saturation at other time points and length of hospital stay. the sample size is 64 children at the age of 6 months to 4 years. if iv-magnesium is effective in relieving viral infection associated bronchial obstruction, that would be an important addition to the treatment of this common disease.

Eligibility criteria:
inclusion criteria: * age 0.5 - 4 years * wheezy bronchitis * rdai \> 6 after conventional treatment exclusion criteria: * prematurity * congenital heart disease * immune deficiency

Keywords: wheezy bronchitis asthma rhinovirus magnesium
validation of a community worker administered stroke symptom questionnaire

Conditions: Stroke

Summary: this is a validation study. a stroke symptom questionnaire will be adapted and translated into local language. two community health workers will be trained in its administration. their findings will be validated against assessment by two neurologists. the study hypothesis is that the chance corrected agreement between the community worker administered stroke symptom questionnaire and the assessment by neurologist based on history and physical examination is at least moderate.

overall objective: to translate, adapt and validate a stroke symptom questionnaire for identification of stroke symptoms by community health workers ( chw) in a peri-urban pakistani community specific aims: 1. to translate and adapt a stroke symptom questionnaire for identification of stroke symptoms by community workers in a peri-urban pakistani community 2. to validate community workers administered stroke symptom questionnaire against assessment by neurologist in a peri-urban pakistani community 3. to determine the feasibility of utilizing community workers for identification of stroke patients in the community in terms of subject refusals and difficulty in understanding questions the study will be conducted at the community site of aman community health project in ibrahim hyderi. community health workers will systematically select households and from them individuals meeting eligibility criteria will be interviewed. community workers will administer stroke symptom questionnaire to them at their homes. those unable to answer will have a surrogate answering for them. in the second part of the study, two neurologists will independently assess all individuals. the purpose of this would be to validate the findings of the community workers based on the stroke symptom questionnaire.

Eligibility criteria:
inclusion criteria: * men and women aged 40 and above * permanent resident of ibrahim hyderi * all ethnicities * can answer for themselves or have a surrogate willing to provide necessary information. surrogate is defined as one who lives in the same household as the individual, who is the primary caregiver and has access to the medical record / information of the patient. * willing to give written informed consent exclusion criteria: - individuals refusing to participate in any of the two components of the study i.e. chw interview or neurological assessment

Keywords: stroke validation community health workers stroke symptom questionnaire
effects of almond versus pistachio on weight loss

Conditions: Obesity; Overweight

Summary: the purpose of the current study is comparing the effect of almond and pistachio, as the two common types of nuts, consumption on healthy obese and overweight female who following a hypocaloric diet for 12 weeks. the secondary aim of the current study is to evaluate of these two type of nuts on other cardiometabolic risk factors.


Eligibility criteria:
inclusion criteria: * must be female * must be 18-45 years of age. * must have body mass index (bmi) between 27-35 kg/ m². * must be able to have moderate exercise. * must be interested to have weight loss. exclusion criteria: * have allergy to nuts * participating in a research project involving weight loss or physical activity in the previous six months. * pregnancy or lactation during the previous 6 months, or planned pregnancy in the next six months. * taking medication that could affect metabolism or change body weight. * report heart problems, chest pain, and cancer within the last five years. * smoking * menopause * diagnosis of any chronic disease such as fatty liver, cancer, chemo/radio therapy, heart disease, immune compromised conditions, abnormal thyroid hormone level.

Keywords: weight loss almond pistachio hypoenergetic diet nut
neuroimaging and neuromonitoring in critically ill children with sepsis

Conditions: Septic Shock

Summary: in critically ill children with severe sepsis, neurophysiologic derangements often proceed undetected and can lead to irreversible brain injury causing neurocognitive and behavioral deficits. the etiology of these impairments is unclear, however, it is likely that some of this neural injury is preventable. the overarching goal for this study is to show that acute acquired structural and microstructural brain injury occurs in critically ill children with severe sepsis, and that this injury is related to neuropsychological deficits and impaired cerebral autoregulation (car). subjects will complete magnetic resonance (mr) imaging within 2-10 days of recognition of their severe sepsis. subjects will undergo serial interrogation of car for up to 10 days. car will be determined by the correlation of arterial blood pressure with middle cerebral artery flow velocity measured by transcranial doppler ultrasonography and cerebral oximetry derived from near-infrared spectroscopy. subjects will also participate in a neuropsychological evaluation 6 months after enrollment to evaluate multiple domains of behavior and cognition.


Eligibility criteria:
inclusion criteria: * admission to the children's hospital of philadelphia (chop) pediatric intensive care unit (picu) * males or females ages ≥ 3.5 years and ≤ 18 years on day of sepsis recognition * meet published consensus criteria for severe sepsis or septic shock: a) ≥ 2 systemic inflammatory response syndrome criteria, b) suspected (based on attending physician) or confirmed systemic infection, and c) ≥ 2 or more organ system dysfunctions (severe sepsis) or cardiovascular dysfunction (septic shock). * an indwelling arterial catheter. * parental/guardian permission (informed consent). * the patient and parent/guardian are fluent in english. exclusion criteria: * history of neurologic disorder including (hypoxic ischemic injury, traumatic brain injury, epileptic encephalopathy, neurodevelopmental, neurometabolic or neurogenetic conditions, and structural brain anomalies). * history of cancer or undergoing treatment for cancer. * meningitis or encephalitis as source of sepsis. * congenital heart disease. * history of cardiac arrest. * history of extracorporeal membrane oxygenation (ecmo) cannulation. * patients with contraindications to mr scanning. * pregnant or lactating females. * parents/guardians or subjects who, in the opinion of the investigator, may be non-compliant with study schedules or procedures. * previous enrollment in this study.
a comparison of visual function after bilateral implantation of presbyopia correcting intraocular lenses

Conditions: Cataract

Summary: to prospectively evaluate postoperative visual and refractive parameters in a series of subjects bilaterally implanted with acrysof restor +3 vs. those bilaterally implanted with lentis mplus intraocular lens (iol).


Eligibility criteria:
inclusion criteria: * are willing and able to understand and sign an informed consent * \<= 1.0 diopters of regular corneal astigmatism in both eyes. note: look for consistency between manual keratometry, auto-keratometry and simulated keratometry measures to ensure "regular" astigmatism prior to enrollment. subjects who wear contact lenses must discontinue its use for at least 2 weeks (soft contact lens) and at least 3 weeks (gas permeable contact lens) and until corneal topography shows stability prior to preoperative study measurements. * are willing and able to attend postoperative examinations per protocol schedule * are more than 21 years of age, of either gender and any race: * require bilateral cataract extraction followed by posterior intraocular lens (iol) implantation used as on-label procedure * be willing to have second eye surgery within one month of first eye surgery * are in good ocular health, with the exception of cataracts * are free of disease(s)/condition(s) listed in the "precautions" section of the acrysof iq restor +3 and lentis mplus package inserts * are able to read and understand one of the following languages: dutch or spanish exclusion criteria: * planned multiple procedures, including limbal relaxing incision (lri), during cataract/iol implantation surgery * an ocular disease and/or condition that may compromise visual acuity levels (i.e. glaucoma, diabetic retinopathy, macular degeneration, amblyopia, pupil abnormality such as corectopia, etc.) * previous corneal surgery and/or reshaping * clinically significant corneal endothelial dystrophy (e.g. fuchs' dystrophy) * history of corneal disease (eg. herpes simplex, herpes zoster keratitis, etc.) * history of retinal detachment * subjects that have an acute or chronic disease or illness that would increase the operative risk or confound the results of this investigation (eg, immunocompromised, connective tissue disease, clinically significant atopic disease, diabetes, and any other such disease or illness). * suturing of incision required at time of surgery

Keywords: intraocular lens presbyopia correcting iol
a study to evaluate safety and pharmacokinetics of vx-659 in healthy subjects and in adults with cystic fibrosis

Conditions: Cystic Fibrosis

Summary: evaluate the safety and tolerability of vx-659 in healthy subjects


Eligibility criteria:
inclusion criteria: healthy volunteers: parts a, b, and c * males and females of non-childbearing potential. * between the ages of 18 and 60 years inclusive * healthy, as defined per protocol. * body mass index (bmi) of 18.0 to 32.0 kg/m2 inclusive * body weight \>50 kg cf patients: part d * body weight ≥35 kg. * males and females of non-childbearing potential. * sweat chloride value ≥ 60 mmol/l at screening. * heterozygous for f508del and a minimal function cftr mutation * forced expiratory volume in 1 second (fev1) ≥40% and ≤90% of predicted at screening exclusion criteria: healthy volunteers: parts a, b, and c * history of any illness or any clinical condition that in the opinion of the investigator might confound the results of the study or pose additional risk to the subject. * any condition possibly affecting drug absorption. * history of febrile illness within 14 days before the first study drug dose. * glucose-6-phosphate dehydrogenase (g6pd) deficiency assessed at screening. cf patients: part d * history of any comorbidity that, in the opinion of the investigator, might confound the results of the study or pose an additional risk to the subject. * history of cirrhosis with portal hypertension. * risk factors for torsade de pointes. * g6pd deficiency assessed at screening. * abnormal laboratory values. * lung infection with organisms associated with a more rapid decline in pulmonary status * history of solid organ or hematological transplantation.
a study of standard treatment +/- apatinib in extensive stage small cell lung cancer

Conditions: Progression Free Survival

Summary: to establish the progression free survival in patients with extensive stage small cell lung cancer treated with cisplatin and etoposide plus or not apatinib

assess progression free survival, overall survival and toxicity of standard ep regimen combined or not with vegf tyrosine kinase inhibitor-apatinib. response measured by recist response criteria. toxicity via physical exam, adverse event review, assessing signs and symptoms, quality of life assessment and blood testing.

Eligibility criteria:
inclusion criteria: 1. histologically or cytologically verified sclc, extensive stages 2. who performance status 0, 1, 2 3. age 18 years or older 4. treatment naive 5. anticipated survival more than 3 months 6. hb \>90g/l, anc\>1.5 x 109/l, platelets \>80 x109 /l 7. no prognancy 8. signed informed consent exclusion criteria: 1. limited stage disease 2. metastastic meningitis, spinal compression, tumor to main vesicular less than 5mm 3. uncontrolled hypertension 4. uncontrolled heart failure 5. coagulation problem 6. surgery, trauma, uncontrolled ulcer in 4 weeks. 7. required by physician
ivermectin as a novel therapy in covid-19 treatment

Conditions: COVID

Summary: efficacy of ivermectin in covid-19 treatment

clinical study evaluating the efficacy of ivermectin in covid-19 treatment

Eligibility criteria:
inclusion criteria: * all adult patients aging from 20 to 65 years-old with covid-19 confirmed by pharyngeal swab pcr. exclusion criteria: * allergy or contraindication to the drugs used in the study. * pregnant and lactating mothers. * patients with cardiac problems.
decreasing unused opioids in the home post supracondylar fracture repair

Conditions: Pain Management

Summary: over the past two decades, the misuse of prescription opioids has significantly increased. a recent systematic review reported as much as 67% to 92% of opioids dispensed on discharge post-surgery go unused. this culture of overprescribing is consistently observed across surgical specialties. less frequently observed is the potential for opioid use and misuse in children and adolescents post-surgery. the research to date in this area has been poorly performed with heterogenous data collection, analysis and reporting, as well as large loss of patients to follow-up. the investigators' previous prospective observational deception study identified three areas of concern: 1. there is a culture of postoperative opioid over-prescribing at discharge as demonstrated by heterogenous opioid dosing and duration of treatments across practitioners for single procedures 2. this overprescribing is in excess of patients' home-requirements and results in significant quantities of leftover opioids 3. there is a culture of inappropriate storage and lack of safe disposal of prescribed opioids in the community

this study focuses on addressing and minimizing pediatric surgical over-prescribing. it aims to reduce the amount of opioids prescribed by focusing prescribers and families on regular use of simple non-opioid analgesics, as well as decreasing the amount of opioids prescribed and dispensed.

Eligibility criteria:
inclusion criteria: * patients with supracondylar fractures undergoing surgical wire placement or pinning that return to fracture clinic at three weeks for removal of pins/wires. * patients discharged on the weekday. * families filling a prescription for opioids at shoppers drug mart at sickkids hospital. * parent has strong command of the english language (i.e., no interpreter required). exclusion criteria: * patients with a history of chronic pain. * patient used opioid medication within the previous 6 months. * patients who are discharged on the weekend (as participant emails will need to be entered into redcap the day of recruitment, for data collection to commence the next morning).